IL-13¹¹ IL-13
Interleukin-13, a 12.5 kDa cytokine secreted primarily by activated Th2 CD4+ T cells, mast cells, and basophils is one of two master regulators of allergic disease — the other being IL-4. While IL-4 orchestrates the initial Th2 commitment and IgE class switching, IL-13 executes the downstream tissue effects: airway smooth muscle contraction, mucus hypersecretion by goblet cells, subepithelial fibrosis, and IgE amplification. Together they form the axis that makes allergic asthma, atopic eczema, and allergic rhinitis chronic rather than self-limiting.

The rs1800925 variant, also written as IL13 -1112C>T, sits in the IL13 gene promoter region on chromosome 5q31 — not in the protein-coding sequence, but upstream of it, in the DNA elements that control when and how much IL-13 gets made. The C allele is the reference and common form. The T allele, carried by about 20% of Europeans and 38% of Africans, silently rewires a key regulatory node in Th2 immune cells.

The Mechanism

The -1112 region of the IL13 promoter normally contains a STAT6 binding motif²² STAT6 binding motif
Signal transducer and activator of transcription 6 — the transcription factor activated downstream of IL-4 and IL-13 receptor signaling, which feeds back to suppress further IL-13 transcription. When STAT6 binds this site in Th2 cells, it partially represses IL13 gene expression, creating a negative feedback brake.

The T allele change at position -1112 disrupts the STAT6 binding motif and simultaneously creates a Yin-Yang 1 (YY1)³³ Yin-Yang 1 (YY1)
A zinc-finger transcription factor with context-dependent activating or repressing functions, named for its ability to act as both activator and repressor depending on cofactors present binding site that overlaps the STAT6 motif. YY1 then competes with STAT6 for binding to this locus. In polarized Th2 cells — exactly the context of active allergic disease — this competition tips in favor of YY1, attenuating STAT6-mediated repression and selectively boosting IL13 transcription⁴⁴ attenuating STAT6-mediated repression and selectively boosting IL13 transcription. The effect is Th2-selective: the same variant has opposing effects in non-polarized T cells, where the nuclear milieu favors STAT6 binding.

The consequence is increased IL-13 production at the tissue level in allergic individuals, which drives goblet cell hyperplasia and mucus secretion in airways, enhances IgE production by B cells (via IL-4Rα/IL-13Rα1 type II receptor), reduces airway responsiveness by altering smooth muscle physiology, and promotes subepithelial fibrosis in chronic disease. Individuals homozygous for the T allele produce measurably more IL-13 from activated Th2 cells.

The Evidence

The -1112C>T functional mechanism was established in 2006 by Cameron et al., who used ChIP assays and EMSA in primary human Th2 cells to show allele-specific STAT6 and YY1 binding at the -1112 locus and confirmed increased IL-13 secretion in TT homozygous subjects⁵⁵ Cameron et al., who used ChIP assays and EMSA in primary human Th2 cells to show allele-specific STAT6 and YY1 binding at the -1112 locus and confirmed increased IL-13 secretion in TT homozygous subjects. This remains the definitive mechanistic study.

Clinical associations span asthma, COPD, and atopic disease. A 2023 meta-analysis (Gaceja et al.) of 11 studies including 2,895 asthma cases and 2,914 controls⁶⁶ 2023 meta-analysis (Gaceja et al.) of 11 studies including 2,895 asthma cases and 2,914 controls found the TT genotype significantly associated with allergic asthma risk in Asian populations under the recessive model (OR 1.48, 95% CI 1.14–1.93) and codominant model (TT vs CC: OR 1.66, 95% CI 1.27–2.17). West Asian populations (Iranian and Saudi) showed the strongest effect (OR 2.17).

For lung disease, a 2017 meta-analysis of 9 studies (Liao et al., 3,077 participants) found the T allele associated with COPD risk overall⁷⁷ 2017 meta-analysis of 9 studies (Liao et al., 3,077 participants) found the T allele associated with COPD risk overall with OR 1.57 (95% CI 1.21–2.04), driven by both Asian (OR 1.88) and Caucasian (OR 1.30) subgroups.

A particularly important pharmacogenomic finding emerged from the CAMP childhood asthma study: Hunninghake et al. (2007) found that the T allele was associated with increased asthma exacerbations specifically in children on inhaled corticosteroids⁸⁸ Hunninghake et al. (2007) found that the T allele was associated with increased asthma exacerbations specifically in children on inhaled corticosteroids (P=0.02) — the first report of a potential negative gene-ICS interaction for this locus. This suggests T carriers may have attenuated corticosteroid benefit from standard inhaled therapy.

The variant also interacts with environmental exposures. Choudhry et al. (2008) demonstrated that IL13 rs1800925 genotype modifies the effect of prenatal tobacco smoke exposure on persistent wheeze in childhood⁹⁹ Choudhry et al. (2008) demonstrated that IL13 rs1800925 genotype modifies the effect of prenatal tobacco smoke exposure on persistent wheeze in childhood, and the NSHD cohort found evidence for smoking-rs1800925 interaction on allergy risk across the life course¹⁰¹⁰ evidence for smoking-rs1800925 interaction on allergy risk across the life course. T carriers who smoke face compounded risk beyond either factor alone.

Practical Actions

For T allele carriers — particularly those with existing atopic disease — the key intervention targets are the IL-4/IL-13 Th2 axis and mucus pathway, alongside monitoring of corticosteroid effectiveness. Since IL-13 itself is now a validated biologic drug target (tralokinumab, lebrikizumab), the biology underlying this SNP is clinically actionable at the therapeutic level.

Total and specific IgE measurement quantifies the downstream consequence of enhanced IL-13 signaling and helps identify the specific allergens being amplified by your Th2 bias. Monitoring IgE trends over time provides objective feedback on whether dietary, supplement, or medication interventions are effective.

For CT carriers with asthma managed on inhaled corticosteroids, the possible ICS-rs1800925 interaction warrants attention to whether current treatment is achieving expected control. If asthma remains poorly controlled despite standard ICS therapy, discussing add-on therapies (LABA, leukotriene modifiers, or biologic options) with a specialist is appropriate.

Interactions

The most important interaction partner is [rs20541 | IL13 R130Q coding variant — the Q130 minor allele (A) directly increases IL-13 protein activity], which is in moderate LD with rs1800925. The -1112T allele increases the amount of IL-13 made; the Q130/rs20541-A allele increases the activity of the protein made. Carrying risk alleles at both loci compounds IL-13 pathway amplification through independent mechanisms — the TA haplotype (rs1800925-T + rs20541-A) is consistently the highest-risk haplotype for atopic disease.

The [rs1801275 | IL4R Q576R — gain-of-function variant in the shared IL-4/IL-13 receptor alpha chain] from the same Th2 pathway amplifies signaling from both IL-4 and IL-13. A carrier of rs1800925-T (more IL-13 produced) with rs1801275-G (more IL-13 signal transduced) faces dual amplification of the same pathway.

Smoking exposure warrants particular attention: multiple studies show that tobacco smoke interacts with rs1800925 genotype to amplify wheeze and allergy risk beyond what either factor alone predicts, likely because smoke-induced airway inflammation further activates Th2 cells that are already primed to over-produce IL-13.

N-acetyltransferase 2 (NAT2) is a Phase II ¹¹ Phase II detoxification conjugates reactive intermediates from Phase I with small molecules to make them water-soluble and excretable detoxification enzyme that adds an acetyl group to aromatic amines and hydrazines, making them water-soluble so your body can excrete them. These substrates include environmental carcinogens from cigarette smoke, heterocyclic amines ²² Heterocyclic amines are carcinogenic compounds formed when meat is cooked at high temperatures, especially charring or grilling from cooked meat, and medications like isoniazid (tuberculosis treatment) and sulfasalazine.

The Mechanism

The I114T variant (rs1801280) changes isoleucine to threonine at position 114 of the NAT2 protein. The C allele (Thr) destabilizes the enzyme, leading to faster degradation and lower acetylation capacity. This is one of the most common "slow acetylator" alleles in European populations, characterizing the NAT2*5B haplotype. The C allele frequency is remarkably high in Europeans (~44%) but very rare in East Asians (~3%).

Slow vs. Rapid Acetylators

NAT2 acetylator status is determined by the combination of multiple variants (rs1801280, rs1799930, rs1208). You need two slow alleles (one from each parent) to be a slow acetylator. About 50-60% of Europeans are slow acetylators ³³ This high frequency suggests slow acetylation may have been advantageous in certain ancestral environments due to the high frequency of these variants, compared to only 10-20% of East Asians.

Clinical Significance

Slow acetylators have increased risk of bladder cancer from occupational exposure to aromatic amines. A major meta-analysis⁴⁴ major meta-analysis
Garcia-Closas M et al. NAT2 slow acetylation and bladder cancer risk. Lancet, 2005 found an overall OR of 1.4 (95% CI 1.2-1.7) for bladder cancer in slow acetylators, with stronger effects in cigarette smokers. Slow acetylators also require dose adjustments for isoniazid and are more prone to drug-induced lupus from certain medications. However, slow acetylation may actually be protective in some contexts - rapid acetylators have higher colorectal cancer risk from heterocyclic amines in well-done meat.

Practical Advice

If you are a slow acetylator: minimize exposure to cigarette smoke (active and secondhand), moderate consumption of heavily charred or grilled meats, and inform your doctor of your acetylator status if prescribed isoniazid or other NAT2 substrate medications.

The TMPRSS3 gene encodes a type II transmembrane serine protease¹¹ type II transmembrane serine protease
Anchored to the cell membrane with its catalytic serine protease domain facing the extracellular space; expressed in cochlear inner and outer hair cells, spiral ganglion neurons, and the stria vascularis essential for the survival of cochlear hair cells at the onset of hearing. Of the more than 87 documented TMPRSS3 pathogenic variants, the p.Ala306Thr missense change caused by c.916G>A is the single most common allele detected across all populations²² the p.Ala306Thr missense change caused by c.916G>A is the single most common allele detected across all populations
Identified in Korean, Chinese, Dutch, and German families; classified as a Korean and Chinese founder mutation; the most frequently reported mutation in published TMPRSS3 literature — making it a high-priority target for both clinical recognition and emerging gene therapy approaches.

This variant is catalogued in ClinVar (variation 46131) as Pathogenic/Likely pathogenic for autosomal recessive nonsyndromic hearing loss 8 (DFNB8), with 17 submitting laboratories providing criteria-based evidence, and no conflicting classifications.

The Mechanism

TMPRSS3 is synthesized as an inactive single-chain precursor (zymogen) that must undergo autocatalytic self-cleavage³³ autocatalytic self-cleavage
The serine protease domain cleaves itself at a specific arginine residue to release the active two-chain form; TMPRSS3 is one of the few serine proteases that activates itself rather than relying on an upstream activator to become active. This active form then contributes to epithelial sodium channel (ENaC) activation in cochlear hair cells and, through as-yet incompletely characterized pathways, supports hair cell survival.

The p.Ala306Thr substitution places a threonine — a bulkier, polar amino acid — at position 306 within the serine protease catalytic domain⁴⁴ serine protease catalytic domain
The catalytic triad of serine proteases (His, Asp, Ser) requires precise spatial arrangement for activity; Ala306 sits adjacent to the active-site residue Asp304, and any perturbation of local geometry can disrupt substrate binding and catalysis. Molecular modeling shows that wild-type Ala306 forms two salt bridges with Thr254, while mutant Thr306 forms an additional unnatural salt bridge with Val291 — a structural perturbation predicted to directly impair catalytic function. Crucially, p.Ala306Thr does not abolish TMPRSS3 autocatalytic processing the way the R216L null allele does; instead it reduces activity, making it a hypomorphic variant⁵⁵ hypomorphic variant
A hypomorph retains partial protein function, as opposed to an amorph (null). TMPRSS3 A306T knockin mice develop delayed-onset progressive hearing loss rather than the complete congenital deafness seen with biallelic null alleles, confirming residual function. The residual activity is insufficient for long-term cochlear hair cell survival but supports initial postnatal hearing — explaining the postlingual, progressive clinical phenotype.

The Evidence

Founder mutation status is established for multiple populations. In the Chinese population⁶⁶ In the Chinese population
Zheng et al. 2017, screening 151 ARNSHL families lacking GJB2/SLC26A4 mutations; TMPRSS3 accounted for 4.6% of cases; c.916G>A was found in 2% of all alleles; haplotype analysis showed linkage disequilibrium across 4/6 families supporting a common ancestor, this allele is clearly a founder mutation. In Korea⁷⁷ In Korea
Carrier rate among Korean postlingual hearing loss patients with TMPRSS3 mutations was 8.3%; p.A306T is the dominant founder allele with haplotype evidence, the same conclusion holds. It has also been independently found in Dutch and German families.

Genotype-phenotype correlations reveal a pattern with clear clinical relevance. Weegerink et al. 2011 in Dutch DFNB8/10 families⁸⁸ Weegerink et al. 2011 in Dutch DFNB8/10 families
8 families studied; the study established the principle that TMPRSS3 allele combinations predict phenotype: two severe alleles → DFNB10 (prelingual profound), one severe + one mild → DFNB8 (postlingual progressive) established p.Ala306Thr as a severe allele. When p.Ala306Thr pairs with a truncating or null allele (such as rs727503493 c.208delC frameshift or rs137853000 R216L), the result is typically prelingual profound hearing loss (DFNB10 phenotype). When it pairs with a mild missense allele, postlingual progressive loss (DFNB8 phenotype) results. This distinction has major clinical implications: DFNB8 patients retain speech for years to decades, while DFNB10 patients require intervention from infancy.

The A306T mouse model provides mechanistic confirmation. Du et al. 2023⁹⁹ Du et al. 2023
Molecular Therapy; CRISPR-Cas9 knockin of the human c.916G>A allele into CBA/CaJ mice created Tmprss3A306T/A306T homozygous animals that develop late-onset progressive HL beginning after 10.5 months, with average threshold elevation of ~26 dB by 22.5 months — exactly recapitulating the human DFNB8 pattern created and validated an A306T knockin mouse model. A single AAV2-hTMPRSS3 injection into 18.5-month-old mice (equivalent to a middle-aged adult human) restored hearing thresholds to wild-type levels, preserved outer hair cell survival, and tripled spiral ganglion neuron survival — making this the first successful gene therapy demonstration in an aged mouse model of hereditary deafness.

Cochlear implant outcomes are favorable. Colbert et al. 2024¹⁰¹⁰ Colbert et al. 2024
127 patients, 16 centers, 6 countries; mean word recognition score 76%; age at implantation is the dominant outcome predictor — each year of delay associated with measurable speech perception decrement confirmed excellent outcomes across the TMPRSS3 patient population. Individual published cases of A306T compound heterozygotes have achieved 65–91% phoneme scores with cochlear implants.

Practical Implications

For confirmed biallelic A306T carriers (TT), or compound heterozygotes carrying one A306T allele and one other pathogenic TMPRSS3 allele, the clinical priority is early audiological characterization, progressive monitoring, and timely cochlear implant referral. The progressive nature of DFNB8 means that TMPRSS3-related hearing loss often presents in childhood with high-frequency loss that progresses over years to decades — a pattern that may be initially confused with noise-induced or idiopathic progressive loss. Genetic diagnosis changes the trajectory by enabling intervention planning.

Looking forward, the AAV-TMPRSS3 gene therapy approach validated in the A306T mouse model represents a genuine therapeutic pipeline specifically targeted to this allele. Carriers with this mutation should be tracked in TMPRSS3 natural history registries that will feed into gene therapy trials.

Interactions

The dominant interaction is compound heterozygosity with other TMPRSS3 pathogenic alleles. Because p.Ala306Thr is a severe (not null) allele:

• A306T + null allele (rs137853000 R216L, rs727503493 c.208delC): Expected DFNB10 — prelingual profound deafness. The null allele contributes no function; A306T's residual activity is insufficient to rescue the phenotype to postlingual onset.
• A306T + mild missense (p.Ala426Thr, p.Ala138Glu, p.Thr248Met, or intronic variants): Expected DFNB8 — postlingual progressive hearing loss, typically onset in childhood to early adulthood, ski-slope audiogram.
• Homozygous A306T/A306T: Also causes DFNB8-type progressive HL; the mouse model Tmprss3A306T/A306T confirms delayed-onset progressive loss, not congenital profound deafness.

The severity-based prediction framework is clinically actionable: when a TMPRSS3 evaluation returns A306T on one allele, comprehensive sequencing of the second allele determines whether the patient faces DFNB8 (mild + mild = postlingual) or DFNB10 (mild + severe = prelingual profound) outcome. See also rs137853000 (R216L, complete null allele) and rs727503493 (c.208delC frameshift) for the other shipped TMPRSS3 pathogenic alleles.

A possible digenic interaction with GJB2 (connexin 26)¹¹¹¹ GJB2 (connexin 26)
GJB2 encodes the gap junction protein connexin 26, the most common cause of genetic hearing loss in most populations; initial reports suggested TMPRSS3/GJB2 digenic cases, but larger series have not confirmed this as a distinct entity has been explored but is not established. When a single TMPRSS3 pathogenic allele is found in a hearing-loss patient, comprehensive deafness gene panel testing including GJB2 should be performed before concluding the patient is a carrier rather than a compound heterozygote.

Inside every pancreatic beta cell, a single enzyme acts as the body's glucose sensor: glucokinase¹¹ glucokinase
Also called hexokinase IV; the rate-limiting enzyme for glucose phosphorylation in beta cells and hepatocytes. By catalyzing the first committed step of glycolysis — converting glucose to glucose-6-phosphate — glucokinase determines the blood glucose concentration at which insulin secretion is triggered. The Ala378Val substitution encoded by this variant disrupts that sensor, shifting the entire glucose threshold for insulin release upward. One copy of this variant (heterozygous state) causes GCK-MODY²² GCK-MODY
Maturity-onset diabetes of the young type 2; also called MODY2. Characterized by lifelong mild fasting hyperglycemia from birth, autosomal dominant inheritance, and low rates of vascular complications, the most common and benign form of monogenic diabetes.

The Mechanism

Alanine 378 sits within the catalytic core of glucokinase, close to the glucose binding site. The substitution of the small, nonpolar alanine with the bulkier valine residue impairs the enzyme's conformational flexibility and reduces its glucose-binding affinity and catalytic rate. In the homozygous state, the Ala378Val variant essentially abolishes glucokinase activity — enzyme kinetics studies show only 0.2% of wild-type activity when both alleles carry this substitution — ³³ Njølstad et al. 2003 — homozygous Ala378Val: activity index 0.2% of wild-type, causing permanent neonatal diabetes with intrauterine growth retardation (Diabetes, PMID 14578306) leading to near-complete glucokinase deficiency and permanent insulin-dependent diabetes from birth.

In the heterozygous state, one functional copy of glucokinase remains. The beta cell still senses glucose, but the set-point is shifted: higher blood glucose concentrations are required before significant insulin secretion is triggered. This results in a stable, mild elevation of fasting blood glucose (typically 5.5–8.0 mmol/L, or 99–144 mg/dL) that is present from birth and does not progressively worsen. The condition is lifelong but largely stable.

The Evidence

GCK-MODY is one of the best-characterized forms of monogenic diabetes. The Osbak et al. 2009 review⁴⁴ Osbak et al. 2009 review
Update on mutations in glucokinase (GCK) which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Human Mutation, 2009 catalogued 620 inactivating mutations across 1,441 families, establishing that heterozygous inactivating GCK mutations uniformly produce MODY2 while homozygous mutations cause permanent neonatal diabetes — a dose-response relationship that reflects the gene's haplosufficiency threshold.

Crucially, long-term follow-up data show that the chronic mild hyperglycemia of heterozygous GCK-MODY does not cause the vascular complications typically seen in type 2 diabetes. Pruhova et al. (2013) found no increase in carotid intima-media thickness in GCK-MODY patients compared with normoglycemic controls, despite decades of elevated fasting glucose. ⁵⁵ Pruhova et al. 2013 — chronic mild hyperglycemia in GCK-MODY does not increase carotid intima-media thickness vs controls, confirming benign vascular course (PMID 24101925) The Ala378Val variant was specifically identified in multiple unrelated individuals with non-autoimmune, non-insulin-deficient monogenic diabetes and meets multiple ACMG/AMP pathogenicity criteria (PP1_Strong, PS4, PM5, PP2, PP3) as reviewed by the ClinGen Monogenic Diabetes Expert Panel in 2023.

Practical Actions

For heterozygous carriers, the clinical implication is that this is not type 1 or type 2 diabetes — it is a distinct condition with a fundamentally different prognosis. Insulin and oral hypoglycemics are generally not recommended for GCK-MODY in the non-pregnant state, as lowering glucose below the genetically elevated set-point can cause hypoglycemia without meaningful long-term benefit. The exception is pregnancy: if the fetus has not inherited the GCK mutation, maternal treatment may be warranted to avoid fetal overgrowth.

Genetic testing of first-degree relatives is important: GCK-MODY is autosomal dominant, so each parent, sibling, and child of a carrier has a 50% probability of carrying the same variant.

Interactions

The fasting glucose set-point in GCK-MODY is independent of, and additive with, common GWAS variants in the same pathway — including the GCK regulatory region (rs1799884) and the glucokinase regulatory protein gene GCKR (rs1260326). These common variants modulate fasting glucose at a population level by a few tenths of a mmol/L, while the Ala378Val pathogenic variant raises the set-point by approximately 1–2 mmol/L — orders of magnitude larger than any common variant effect. Compound heterozygosity with other GCK inactivating mutations, though theoretically possible, is extremely rare; homozygosity for Ala378Val produces the severe neonatal phenotype described by Njølstad et al.

CYP3A4 is the most versatile drug-metabolizing enzyme in the human body, responsible for processing approximately 50% of all prescription medications — from transplant immunosuppressants and statins to psychiatric drugs and opioids. The *1G variant (rs2242480) sits in intron 10 of CYP3A4, a seemingly innocuous location. Yet its effects on enzyme expression are clinically meaningful enough to appear on transplant pharmacogenomics panels and to influence tacrolimus and sirolimus trough concentrations by two- to three-fold in transplant patients.

Unlike the well-characterized *22 splice variant (rs35599367), *1G does not disrupt a splicing factor binding site. Instead, its mechanism runs through an indirect regulatory pathway involving a long noncoding RNA.

The Mechanism

Collins and Wang (2022)¹¹ Collins and Wang (2022)
Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the CYP3A4*1G association identified AC069294.1, an antisense [long noncoding RNA | lncRNA: a class of RNA molecules longer than 200 nucleotides that do not code for protein but regulate gene expression] as a negative regulator of both CYP3A4 and CYP3A5. Knockdown of this lncRNA increased CYP3A4 mRNA approximately 3-fold; overexpression reduced it by 89%. The rs2242480 T allele (*1G) sits approximately 2.7 kb upstream of the lncRNA gene and is associated with 1.26-fold increased lncRNA expression (P<0.0001). Downstream of this, *1G carriers show 31% lower CYP3A4 expression (P=0.008) and 39% lower CYP3A5 expression (P=0.004). Yang et al. (2023)²² Yang et al. (2023)
CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells confirmed this in engineered cell lines, showing allele-dependent reduction in both mRNA and protein, with decreased tacrolimus metabolism particularly in heterozygous GA (plus-strand: CT) cells.

On the chromosome, CYP3A4 lies on the minus strand. The variant is described in coding-strand notation as c.1026+12G>A, but in genome files (which always use the plus strand), it reads as a C>T change at chromosome 7 position 99,763,842 (GRCh38). The reference allele C corresponds to the wild-type *1 haplotype; the alternate T allele defines *1G.

The Evidence

The most clinically relevant evidence comes from transplant medicine. Miura et al. (2011)³³ Miura et al. (2011)
Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients followed 136 renal transplant recipients and found that CYP3A4*1G carriers had significantly lower dose-adjusted tacrolimus AUC and trough concentrations — an effect approximately half the magnitude of CYP3A5 expresser status but independently significant (P=0.018). Dong et al. (2022)⁴⁴ Dong et al. (2022)
CYP3A7, CYP3A4, and CYP3A5 polymorphisms in recipients influence tacrolimus concentrations after liver transplantation found CC recipients had approximately twice the dose-adjusted trough concentration as TC/TT carriers (189.8 vs 99.7 ng/mL per mg/kg/day, P<0.001) in 138 liver transplant patients. Uesugi et al. (2013)⁵⁵ Uesugi et al. (2013)
CYP3A4*1G polymorphism and tacrolimus in liver transplant patients observed similar direction effects in a 410-patient Japanese cohort, with CYP3A4*1/*1 donors yielding 37% higher concentration/dose ratios than *1/*1G donors in the first week post-transplant.

For sirolimus, a 2020 study of 69 renal transplant recipients⁶⁶ a 2020 study of 69 renal transplant recipients
CYP3A4 rs2242480 associated with sirolimus trough concentrations found CC carriers achieved 533 vs 157–143 (ng/mL)/mg/kg trough concentrations compared to TC and TT carriers respectively (P<0.0001) — a greater than three-fold difference that could mean the difference between subtherapeutic and supratherapeutic exposure.

Beyond transplant medicine, a meta-analysis of 18 studies encompassing 2,546 epilepsy patients⁷⁷ a meta-analysis of 18 studies encompassing 2,546 epilepsy patients
Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism found the *1G allele (G in coding-strand notation, T in plus-strand) markedly reduced plasma carbamazepine concentrations. For psychiatric drugs, Dai et al. (2026)⁸⁸ Dai et al. (2026)
CYP3A4 rs2242480 and lurasidone in Chinese bipolar depression modeled 133 patients and found CC carriers had 25% lower lurasidone clearance than TT carriers (330 vs 441 L/h), translating to meaningfully higher drug exposure at equivalent doses.

Practical Actions

The primary clinical application of CYP3A4*1G genotyping is in transplant medicine, where tacrolimus and sirolimus have narrow therapeutic windows — the difference between rejection and toxicity. CC homozygotes (the wild-type) metabolize CYP3A4 substrates efficiently and require standard doses. CT heterozygotes (*1/*1G) have moderately reduced enzyme activity; for tacrolimus and sirolimus, starting doses may need upward adjustment or more frequent monitoring to reach target trough levels. TT homozygotes (*1G/*1G) have the greatest reduction in CYP3A4 expression and the lowest drug clearance; they may achieve target tacrolimus/sirolimus levels at lower doses than standard, reducing nephrotoxicity risk.

For CYP3A4-metabolized statins (atorvastatin, simvastatin, lovastatin), TT carriers accumulate higher statin levels and may be at increased risk of myopathy at standard doses. The statin evidence is more limited than for immunosuppressants, but the directionality is consistent.

Interactions

CYP3A4*1G and CYP3A4*22 (rs35599367) are independent variants in the same gene. A patient carrying both the *1G and *22 alleles would be expected to have compounded reductions in CYP3A4 activity. Similarly, CYP3A5 expresser status (rs776746 *1/*3) strongly modifies the *1G effect — Miura et al.⁹⁹ Miura et al.
Tacrolimus PKs in renal transplant showed the lowest dose-adjusted AUC occurred in patients who were both *1G carriers and CYP3A5 expressers, because CYP3A5 expression itself boosts metabolic capacity that the *1G variant then partially suppresses. For a complete picture of CYP3A metabolizer phenotype, both rs2242480 (*1G) and rs776746 (CYP3A5*3) should be considered together.

Every time you eat, your small intestine releases a hormone called GIP (glucose-dependent insulinotropic polypeptide)¹¹ GIP (glucose-dependent insulinotropic polypeptide)
Also called gastric inhibitory polypeptide. One of two major incretin hormones that amplify insulin release after a meal and suppress appetite via the gut-brain axis. GIP works alongside GLP-1 to drive up to 70% of the insulin your pancreas secretes after eating — a system called the incretin effect. The rs2291725 variant in the GIP gene changes a single amino acid at position 103 of the precursor protein (Serine → Glycine), altering the bioactivity of the mature hormone.

This variant is unusual in human genetics: the Glycine form (C allele on the plus strand) appears to have undergone positive selection²² positive selection
Evolutionary selection where a beneficial variant spreads faster through a population than neutral drift would explain in Eurasian populations roughly 8,100 years ago — approximately when agriculture was expanding across Eurasia. The derived allele now reaches 71.8% in East Asian populations and 52.7% in Europeans, while remaining rare in African populations (11.6%), where the ancestral Serine form predominates at 88.4%.

The Mechanism

The Ser→Gly substitution at GIP amino acid 55 (position 103 in the prepropeptide) alters the biochemical behavior of the mature hormone in two ways, as shown by Chang et al. 2011³³ Chang et al. 2011
Chang CL et al. Adaptive selection of an incretin gene in Eurasian populations. Genome Research, 2011:

First, the Gly variant (C allele, GIP55G) generates significantly higher cAMP⁴⁴ cAMP
Cyclic AMP — the intracellular second messenger that GIP triggers in pancreatic beta cells and adipocytes to drive insulin secretion production in GIPR-expressing cells compared to the ancestral Ser form (GIP55S), with a statistically significant difference (p < 0.01). This means stronger receptor activation per molecule of hormone released.

Second, the Gly variant is more resistant to serum degradation, giving the hormone a longer effective half-life in circulation. The ancestral Ser form is cleaved more readily by dipeptidyl peptidase-4 (DPP-4)⁵⁵ dipeptidyl peptidase-4 (DPP-4)
The enzyme that rapidly inactivates both GIP and GLP-1 by removing their first two amino acids; DPP-4 inhibitors (gliptins) work by blocking this degradation, shortening its active window. Together, higher intrinsic potency and greater stability mean carriers of the Gly allele experience more powerful postprandial incretin signaling per meal.

GIP receptors are expressed not only in the pancreas and adipose tissue but also in the hypothalamus, hippocampus, and brainstem — areas that regulate appetite, reward, and the sleep-wake interface. This gut-brain axis expression explains why GIP variation appears in large-scale GWAS of sleep phenotypes alongside its better-characterized metabolic roles.

Importantly, GIP is one of two targets of tirzepatide (Mounjaro / Zepbound), the dual GIP/GLP-1 receptor agonist. Genetic variation in GIP and GIPR (the receptor gene) is increasingly recognized as relevant to treatment response prediction for this drug class.

The Evidence

Chang et al. (2011)⁶⁶ Chang et al. (2011)
Chang CL et al. Adaptive selection of an incretin gene in Eurasian populations. Genome Research, 2011 analyzed 944 individuals across global populations from the HGDP-CEPH cohort and identified clear signatures of positive selection for the derived C allele in Eurasian — particularly East Asian — populations. The empirical selection p-values ranged from 0.004 to 0.058 across population comparisons. In functional assays, GIP55G showed higher cAMP production (p < 0.01) and greater serum stability (p = 0.002) than GIP55S, suggesting that enhanced incretin response to dietary carbohydrate may have conferred survival advantage in agricultural societies.

A cardiovascular risk study in 666 Chinese type 2 diabetic patients by Ma et al. (2018)⁷⁷ Ma et al. (2018)
Ma X et al. Genetic variability of the GIP gene is involved in premature coronary artery disease in Chinese patients with T2D. J Diabetes Res, 2018 found that, in individuals with premature CAD (men <55, women <65), carriers of the C allele had higher CAD risk than non-carriers (OR 1.627, p = 0.015), while T/T or T/C genotypes (with at least one ancestral T allele) were associated with lower CAD risk (adjusted OR 0.769, p = 0.013). This paradoxical finding — the higher-bioactivity allele conferring CAD risk in the context of established diabetes — suggests the relationship between GIP activity and cardiovascular outcomes is mediated by metabolic context rather than being a simple dose-response.

The Lane et al. (2019) insomnia GWAS⁸⁸ Lane et al. (2019) insomnia GWAS
Lane JM et al. Biological and clinical insights from genetics of insomnia symptoms. Nature Genetics, 2019 conducted in 453,379 UK Biobank participants identified 57 genome-wide significant loci for insomnia symptoms, with mapped biological pathways enriched for gut-brain signaling and metabolic hormone networks. The GIP locus on chromosome 17q21 sits within a region showing pleiotropic associations across metabolic, sleep, and cardiovascular traits.

A large coronary artery disease GWAS by the CARDIoGRAMplusC4D Consortium (2011)⁹⁹ by the CARDIoGRAMplusC4D Consortium (2011)
Schunkert H et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics, 2011 confirmed the 17q21 locus — which encompasses GIP — as genome-wide significant for CAD (n > 22,000 cases).

Practical Actions

The key modifiable variable in GIP biology is meal timing and composition. GIP is secreted within minutes of eating fat and carbohydrate — its release is driven by nutrient contact with K-cells in the proximal small intestine. For carriers of the lower-bioactivity Ser allele (T/T), optimizing meal timing relative to sleep may help compensate for the weaker postprandial incretin signal. Finishing eating at least 3–4 hours before bed reduces the nocturnal GIP stimulation that can fragment sleep architecture in individuals with altered gut-brain hormonal signaling.

GIP also directly promotes fat storage in adipocytes (it upregulates LPL activity and promotes triglyceride uptake), so carriers of two copies of the T allele — with lower GIP bioactivity — may have different fat partitioning responses to high-fat vs high-carbohydrate diets than Gly/Gly carriers.

For users taking or considering tirzepatide (which agonizes both the GIP and GLP-1 receptors), variants in the GIP gene pathway are increasingly being studied as potential response modifiers. The ancestral Ser form (T allele) may be associated with lower endogenous GIPR activation, potentially altering the pharmacological response landscape.

Interactions

GIP works in concert with GLP-1 (encoded by GCG on chromosome 2) and the GIP receptor (GIPR, chromosome 19). GIPR variants — particularly rs1800437 (E354Q) — modify receptor sensitivity and are separately catalogued. The combined effect of GIP Ser103Gly (rs2291725) and GIPR variants on incretin potency and sleep quality is a plausible compound interaction: individuals with both a lower-bioactivity GIP ligand (T/T) and a reduced-sensitivity GIP receptor may have the most attenuated gut-brain incretin signaling.

The GIP locus at 17q21 lies near genes involved in coronary artery disease (UBE2Z, ATP5G1, SNF8). Functional interaction with rs46522 (UBE2Z-GIP locus) in the context of T2D risk has been reported, though this reflects LD structure rather than direct gene-gene interaction.

Adiponectin is the most abundant adipokine the body produces, secreted almost exclusively by fat tissue and acting as a master regulator of insulin sensitivity¹¹ master regulator of insulin sensitivity
a hormone that activates AMPK in muscle and liver, suppresses hepatic glucose output, and reduces inflammation throughout the vascular system. The ADIPOQ gene's promoter region — the molecular switch that determines how actively the gene is transcribed — contains several functional variants that alter circulating adiponectin levels. The rs266729 variant sits approximately 11,391 base pairs upstream of the ADIPOQ transcription start site, where a C-to-G substitution at this position demonstrably dampens gene expression and lowers adiponectin output in carriers.

This SNP is catalogued at dbSNP as a 2 KB upstream regulatory variant at chromosome 3 position 186,841,685 (GRCh38). The G allele has been consistently identified across independent meta-analyses as a low-penetrant but replicable risk factor for type 2 diabetes, non-alcoholic fatty liver disease, and cardiovascular disease — driven primarily by reduced adiponectin transcription that impairs the body's natural insulin-sensitizing and anti-inflammatory signalling.

The Mechanism

The rs266729 C>G substitution alters a transcription factor binding site²² transcription factor binding site
proteins that attach to specific DNA sequences and drive or repress gene expression in the ADIPOQ proximal promoter. Electrophoretic mobility shift assays have demonstrated that the G allele reduces the binding affinity of activating transcription factors at this site, lowering ADIPOQ transcriptional activity relative to the C allele. The downstream consequence is reduced circulating adiponectin — particularly the high-molecular-weight (HMW) multimeric form that drives insulin sensitisation and vascular protection.

Adiponectin signals through two receptors: AdipoR1³³ AdipoR1
predominantly in skeletal muscle; activates AMPK to increase fatty acid oxidation and glucose uptake and AdipoR2⁴⁴ AdipoR2
predominantly in liver; activates PPARα to reduce lipid accumulation and hepatic inflammation. When adiponectin levels are chronically low because the promoter runs quiet, both pathways are under-activated: insulin sensitivity falls, hepatic fat accumulates, vascular inflammation rises, and the risk of metabolic disease increases across multiple organ systems.

The Evidence

The landmark meta-analysis by Sun et al.⁵⁵ Sun et al.
7 studies, 12,323 total subjects established that the G allele increases T2D risk with a generalized odds ratio of 1.13 (95% CI 1.02–1.25) and an additive model OR of 1.13 per G allele (95% CI 1.06–1.19). An earlier meta-analysis by Gong et al.⁶⁶ Gong et al.
10,267 T2D cases and 12,837 controls across multiple ethnicities found a very similar estimate: G allele OR 1.08 (95% CI 1.01–1.15, P=0.034), classifying rs266729 as "a low-penetrant risk factor for developing T2D."

Cardiovascular risk is compounded. A comprehensive meta-analysis by Kanu et al.⁷⁷ Kanu et al.
65 studies, 19,106 CVD cases and 31,629 controls found significant increases in cardiovascular disease risk for rs266729 in both the dominant and heterozygote genetic models. Trial sequential analysis confirmed sufficient evidence "to reach concrete conclusions."

Non-alcoholic fatty liver disease (NAFLD) shows particularly strong genotype-dose effects. Zheng et al.⁸⁸ Zheng et al.
systematic review and meta-analysis, 2,619 NAFLD cases and 1,962 controls across 10 studies found that the G allele nearly doubled NAFLD risk in the allelic model (OR 1.72, 95% CI 1.34–2.21) and that GG homozygotes faced a 2.69-fold risk increase (95% CI 1.84–3.92). Associations were consistent across Asian and Caucasian populations.

At the tissue level, Divella et al.⁹⁹ Divella et al. demonstrated in colorectal cancer patients that CG and GG carriers have significantly lower circulating adiponectin than CC homozygotes (P=0.034), confirming the functional consequence of the transcriptional impairment. G allele carriers also showed elevated TNF-α, connecting reduced adiponectin to heightened inflammatory signalling.

Practical Actions

The rs266729 G allele's primary effect is reduced adiponectin output, which means interventions that naturally boost adiponectin expression are particularly relevant. Omega-3 fatty acids (EPA and DHA) activate PPARγ in adipocytes¹⁰¹⁰ activate PPARγ in adipocytes
the master transcriptional regulator of adipogenesis and adiponectin secretion, stimulating ADIPOQ transcription and partially compensating for reduced promoter activity. In randomised trials, 3–4 g/day EPA/DHA supplementation raises adiponectin by 10–25% in insulin-resistant individuals.

Dietary fat composition also modulates ADIPOQ expression through PPARγ. Monounsaturated fatty acids (olive oil, avocados, almonds) and polyunsaturated fats preferentially activate PPARγ, while saturated fat suppresses it. For G allele carriers whose promoter is already operating at reduced capacity, minimising saturated fat and replacing it with MUFA or PUFA has the most evidence for raising adiponectin toward protective levels.

Monitoring adiponectin levels directly is meaningful for this genotype — particularly if other metabolic risk factors are present. Low adiponectin (<5 µg/mL in men, <8 µg/mL in women) substantially amplifies the risk of the associated conditions, and tracking changes in response to dietary intervention gives direct feedback on whether the compensation is working.

Interactions

rs266729 is in moderate-to-high linkage disequilibrium with rs17300539 (-11391G>A), the other functional ADIPOQ promoter SNP already on the platform, as well as with rs2241766 (+45T>G, Gly15Gly in exon 2) and rs1501299 (+276G>T, intron 2). Haplotype combinations across these four variants produce stronger effects on adiponectin levels than any single SNP alone — the A-C haplotype combining rs17300539-A and rs266729-C is associated with greater adiponectin elevation and better lipid outcomes after bariatric surgery than either allele alone.

Emerging data suggest interaction with TCF7L2 variants (particularly rs7903146): TCF7L2 regulates adipocyte differentiation and function, and the combination of TCF7L2 T-allele risk with reduced adiponectin from rs266729 G-allele may identify individuals with the highest dietary fat sensitivity. This interaction candidate is described for supervisor review.

Apolipoprotein C-III (apoCIII) is the body's master brake on triglyceride clearance. It coats triglyceride-rich VLDL particles and inhibits the lipoprotein lipase¹¹ lipoprotein lipase
The enzyme that breaks down triglycerides in blood, releasing fatty acids for tissues that would otherwise clear them. After a meal, healthy physiology suppresses apoCIII secretion — letting triglycerides clear quickly. The rs2854117 variant disrupts that suppression, keeping apoCIII elevated and triglycerides circulating longer.

The Mechanism

The APOC3 gene sits on chromosome 11 in a cluster with APOA1, APOA4, and APOA5. Its promoter contains a negative insulin response element (nIRE)²² negative insulin response element (nIRE)
A DNA sequence where insulin binding normally represses gene transcription that ordinarily drives down APOC3 output after eating. The C-482T variant (T allele at rs2854117) lies within this nIRE, altering its sequence and blunting the insulin signal that should silence APOC3. The result is persistently elevated apoCIII protein, which keeps VLDL particles circulating and slows triglyceride clearance from the bloodstream.

The -482 position is in strong linkage disequilibrium with rs2854116 (T-455C), and the two variants are usually studied together as part of an APOC3 promoter haplotype. Both sit within the same nIRE, and their combined effect on insulin-mediated suppression appears additive.

The Evidence

A 2003 prospective cohort study in 502 adults³³ 2003 prospective cohort study in 502 adults
Waterworth et al. Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003 found that T allele homozygotes had a 33% lower 30-minute insulin increment after glucose challenge, and approximately 10% higher non-esterified fatty acid (NEFA) levels, compared to CC homozygotes. Both variants (at -482 and -455) also interacted with smoking to worsen fasting triglycerides.

A 2001 epidemiological study in 983 French adults⁴⁴ 2001 epidemiological study in 983 French adults
Dallongeville et al. Polymorphisms in the insulin response element of APOC-III gene promoter influence the correlation between insulin and triglycerides. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001 confirmed that the -482 T allele modifies the relationship between plasma insulin and triglyceride-rich LpCIII:B particles, particularly in women.

The most direct disease-risk evidence comes from a 2025 Chinese case-control study in 440 participants⁵⁵ 2025 Chinese case-control study in 440 participants
Ye et al. Associations between APOC3 and ANGPTL8 gene polymorphisms with MASLD risk. 2025, which found that CT+TT carriers had 1.9-fold higher odds of metabolic dysfunction-associated steatotic liver disease (MASLD) compared with CC carriers (OR 1.9, 95% CI 1.2–3.2), with triglycerides mediating 62.6% of that genetic effect.

Pharmacogenomic data from the GOLDN trial⁶⁶ GOLDN trial
Liu et al. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate. Pharmacogenetics and Genomics, 2009 showed that the T minor allele is associated with a blunted triglyceride-lowering response to fenofibrate (p=0.026), unlike other variants in the same cluster which enhance the response. This suggests the -482 variant alters the transcriptional pathway fenofibrate relies on.

Evidence is mixed on broader cardiovascular endpoints: a meta-analysis found no significant association with ischemic stroke⁷⁷ found no significant association with ischemic stroke
Zhang et al. The impact of APOA5, APOB, APOC3 and ABCA1 gene polymorphisms on ischemic stroke. Gene, 2017, and studies in European cohorts have not consistently shown a NAFLD/liver-fat association, suggesting ethnic and dietary context modulate the phenotypic expression.

Practical Actions

T allele carriers should focus on the two levers most directly linked to apoCIII activity: dietary fat quality and post-meal triglyceride clearance. Limiting refined carbohydrates and fructose is particularly relevant because both raise apoCIII transcription independently of the promoter variant. Long-chain omega-3 fatty acids (EPA and DHA) suppress apoCIII at the transcriptional level, partially compensating for the blunted insulin signal.

Fasting triglyceride testing is the most direct way to track phenotypic expression of this variant. Levels consistently above 150 mg/dL suggest the variant is having a meaningful effect and warrant dietary intervention. Fenofibrate may have a reduced effect in T carriers; if fibrate therapy is being considered, this variant is worth noting to the prescribing clinician.

Interactions

rs2854117 is in strong linkage disequilibrium with rs2854116 (T-455C, the other APOC3 promoter nIRE variant). Carriers of the T allele at rs2854117 are very likely to also carry the C allele at rs2854116. Studies generally show additive effects on apoCIII dysregulation when both promoter variants are co-inherited. The APOC3 3'-SstI variant (rs5128) operates through a different mechanism (post-transcriptional or 3'-regulatory) and has independent effects on VLDL — its effect can stack with the promoter haplotype.

The APOA5 rs662799 variant is a frequent companion in hypertriglyceridemia genetic panels and encodes a different step in the VLDL-triglyceride axis. When rs662799 risk allele co-occurs with the rs2854117 T allele, the combined triglyceride burden is likely additive, though published compound analyses are limited.

The glucocorticoid receptor gene NR3C1 encodes the primary cellular transducer of cortisol signaling — a protein that, when activated, reshapes gene expression programs governing inflammation, metabolism, immune function, and the molecular hallmarks of cellular aging. This intronic variant (rs2918418) is the third of three NR3C1 variants identified in the same Polish centenarian study, alongside rs2963154¹¹ rs2963154 and rs10515522²² rs10515522, both of which showed related but stronger longevity associations.

The finding for rs2918418 inverts the allele-frequency pattern seen in its sister variants: here it is the rare CC genotype (approximately 2% of Europeans) that is enriched among those who reached ages 95–106, while the common GG genotype carries the cholesterol-elevation signal. This means that in most people the common genotype — not the rare one — marks the metabolic disadvantage, offering an interpretive window into how this locus may contribute to population-level aging trajectories.

The Mechanism

rs2918418 sits at chromosome 5, position 143,343,808 (GRCh38), within an intron of NR3C1. The NR3C1 gene is transcribed from the minus strand; the plus-strand alleles are G (reference, major, ~85%) and C (alternate, minor, ~15%). This is a simple C/G SNP at an intron position with no protein-coding consequence. The mechanism, as with rs2963154 and rs10515522, is most likely regulatory: altered NR3C1 transcription rate, splicing efficiency, or the relative production of the major GRα versus glucocorticoid-resistant GRβ isoforms.

The cholesterol-elevation signal for the GG genotype fits within an established mechanistic framework. A 2025 study in the Journal of Clinical Investigation³³ A 2025 study in the Journal of Clinical Investigation
Durumutla et al. The human glucocorticoid receptor variant rs6190 increases blood cholesterol and promotes atherosclerosis. J Clin Invest. 2025 demonstrated that altered GR transactivation in liver cells directly upregulates PCSK9 and BHLHE40 — negative regulators of LDL and HDL receptor expression respectively — resulting in elevated circulating LDL and total cholesterol. NR3C1 intronic variants that alter GR expression level or isoform ratio in hepatocytes would access this same pathway. The GG genotype's association with both elevated total cholesterol (p = 0.03) and LDL cholesterol (p = 0.03) is particularly notable because LDL elevation is a direct cardiovascular risk factor, not merely an incidental metabolic marker.

The rare CC genotype's enrichment in centenarians suggests it may confer a hepatic glucocorticoid signaling environment less prone to GR-driven LDL elevation — potentially a more favorable metabolic set point maintained across decades. This remains speculative given the intronic location and absence of direct functional characterization.

The Evidence

All three rs2918418 findings emerge from a single cohort study. Olczak et al. (2019)⁴⁴ Olczak et al. (2019)
Glucocorticoid receptor (NR3C1) gene polymorphisms are associated with age and blood parameters in Polish Caucasian nonagenarians and centenarians. Exp Gerontol. 2019;116:20-24 genotyped three NR3C1 intronic variants in 552 long-lived subjects (ages 95–106) and 284 cord blood controls of Polish Caucasian ancestry.

For rs2918418, two statistically significant associations were reported: the CC genotype was more frequent in the long-lived cohort (p = 0.028), and the GG genotype was specifically associated with elevated total cholesterol (p = 0.03) and LDL cholesterol (p = 0.03) within the centenarian population. The longevity association (p = 0.028) is the weakest of the three NR3C1 variants studied — rs2963154 showed p = 0.002 for TT enrichment and rs10515522 showed p = 0.016 for TT enrichment. Importantly, rs2918418 is the only one of the three variants where the rare homozygote, rather than the common genotype, shows the longevity enrichment.

The LDL finding is particularly actionable: unlike HDL, which has complex and context-dependent cardiovascular consequences at elevated levels, elevated LDL is a well-established independent cardiovascular risk factor. The GG genotype's association with both elevated total cholesterol and LDL in an elderly cohort who have survived to extreme age suggests this genotype imposes a lipid-metabolism burden that persists even in robust long-term survivors.

No independent replication of this specific variant's longevity or cholesterol associations has been published. The variant does not appear in GWAS catalog hits for lipid traits or longevity phenotypes in larger European cohorts, consistent with a modest or population-specific effect. The evidence level is emerging.

Practical Implications

For the majority of people carrying the GG genotype, the association with elevated LDL and total cholesterol in the oldest-old argues for proactive lipid monitoring — not as a response to current disease, but as a mechanism to detect GR-driven hepatic cholesterol dysregulation before it accumulates cardiovascular risk over decades. The GR-to-PCSK9 pathway is pharmacologically relevant: if LDL elevation is detected and partially driven by altered NR3C1 hepatic signaling, PCSK9 inhibitors (evolocumab, alirocumab) target the mechanism more precisely than dietary LDL reduction alone.

For the rare CC carriers, no longevity intervention is warranted — the CC enrichment in centenarians reflects a favorable metabolic background, not a pharmacological target. The practical value is contextual: CC status provides reassurance that this particular NR3C1 locus is not contributing to GR-driven LDL elevation.

Interactions

rs2918418 operates in the same gene as three other NR3C1 variants in the GeneOps database: rs6198 (9β)⁵⁵ rs6198 (9β), which favors the glucocorticoid-resistant GRβ isoform and blunts cortisol response; rs41423247 (BclI)⁶⁶ rs41423247 (BclI), which increases GR sensitivity to glucocorticoids; and rs2963154⁷⁷ rs2963154, whose TT genotype is the strongest longevity signal in the same cohort.

The three longevity variants (rs2918418, rs2963154, rs10515522) were studied together in the same population and may partially tag overlapping regulatory haplotypes within the NR3C1 intron. A person carrying GG at rs2918418, CC at rs2963154 (elevated cholesterol + depleted from centenarians), and TT at rs10515522 (no survival benefit) would accumulate a full unfavorable NR3C1 longevity profile — a combination that warrants cholesterol surveillance regardless of which individual variant drives the effect.

The WNT16 gene encodes a signaling protein¹¹ signaling protein
WNT16 is a member of the Wingless-related integration site (WNT) family of secreted glycoproteins that regulate bone homeostasis crucial for bone development and maintenance. Among all the WNT family members, WNT16 stands out for its specific and powerful effect on cortical bone — the dense outer layer of bone that provides structural strength and accounts for about 80% of the skeleton's mass. The rs3801387 variant lies in the last intron of WNT16 and is part of a regulatory region²² regulatory region
The variant is in high linkage disequilibrium with other functional variants including eQTLs that affect WNT16 and neighboring gene expression that influences how much WNT16 protein your bone cells produce.

The Mechanism

WNT16 is primarily expressed by osteoblasts³³ primarily expressed by osteoblasts
bone-forming cells lining the cortical bone surface, where it plays a dual role in maintaining bone strength. First, it acts directly on osteoclast precursors to inhibit their differentiation into bone-resorbing osteoclasts through a non-canonical signaling pathway. Second, it increases expression of osteoprotegerin (OPG) in osteoblasts, which acts as a decoy receptor for RANKL, further suppressing osteoclastogenesis. The net result is reduced bone resorption on the inner (endocortical) surface, preserving cortical thickness.

The rs3801387 variant affects this system through regulatory mechanisms. The A allele is associated with lower bone mineral density⁴⁴ A allele is associated with lower bone mineral density, while the G allele appears protective, correlating with higher BMD and thicker cortical bone. In a region of high linkage disequilibrium spanning WNT16 and the adjacent FAM3C gene, rs3801387 tags multiple functional variants that influence gene expression. This makes rs3801387 a reliable proxy for overall WNT16 function, which is why it has emerged as the sentinel SNP in multiple GWAS⁵⁵ sentinel SNP in multiple GWAS for bone traits.

The Evidence

Multiple large-scale studies have established rs3801387's role in bone health. A GWAS meta-analysis of cortical bone thickness in 5,878 individuals⁶⁶ GWAS meta-analysis of cortical bone thickness in 5,878 individuals identified WNT16 variants associated with both cortical thickness and forearm BMD at genome-wide significance (P = 6.2×10⁻⁹ for cortical thickness). The study also demonstrated association with forearm fracture risk (OR = 1.33 for fractures, P = 7.3×10⁻⁹). A meta-analysis restricted to premenopausal women (n=4,061)⁷⁷ meta-analysis restricted to premenopausal women (n=4,061) found rs3801387 reached genome-wide significance for lumbar spine BMD (P = 1.7×10⁻⁹ in discovery, improving to P = 1.3×10⁻¹¹ in joint analysis). Each copy of the minor G allele was associated with approximately 0.16 SD higher BMD, explaining 0.6-1.8% of BMD variance.

Functional validation came from Wnt16 knockout mice⁸⁸ Wnt16 knockout mice, which developed spontaneous fractures due to 27% thinner cortical bone and high cortical porosity. Bone strength was reduced by 43-61% at both femur and tibia. Critically, trabecular (spongy) bone was unaffected, confirming WNT16's cortical-specific role. The effect persists through the lifespan — conditional inactivation in adult mice⁹⁹ conditional inactivation in adult mice showed that WNT16 continues to regulate cortical thickness even after peak bone mass is achieved, suggesting interventions targeting this pathway could benefit older adults.

Interestingly, the effect of rs3801387 may interact with mechanical loading. A study of male endurance runners¹⁰¹⁰ male endurance runners found AA genotype runners had 14% lower lumbar spine BMD than AA genotype non-athletes (P < 0.001), while AG+GG genotype runners actually had 5% higher leg BMD than non-athletes. This suggests that in individuals with lower baseline WNT16 function (AA genotype), the repetitive loading of endurance running may not adequately compensate for reduced WNT16-mediated osteoclast suppression.

Practical Implications

Your genotype at rs3801387 provides insight into your cortical bone health trajectory, particularly your risk of non-vertebral fractures — those occurring at the hip, wrist, and other sites rich in cortical bone. Non-vertebral fractures cause enormous disability and mortality in older adults, yet existing osteoporosis treatments have only marginally reduced their incidence compared to the dramatic reductions seen for vertebral fractures. Understanding your genetic predisposition allows for earlier and more targeted preventive measures.

If you carry the AA genotype (higher risk), optimizing peak bone mass in early adulthood and minimizing bone loss thereafter becomes especially important. This means ensuring adequate calcium (1,000-1,200 mg/day) and vitamin D (800-1,000 IU/day for adults over 50) throughout life. Weight-bearing exercise ¹¹¹¹ Weight-bearing exercise is the single best intervention for cortical bone, as mechanical loading stimulates periosteal (outer surface) bone formation. For AA individuals who participate in high-volume endurance exercise, monitoring bone density and potentially incorporating resistance training may be particularly important.

Because WNT16 specifically affects cortical bone, standard DEXA scans of the hip and forearm (cortical-rich sites) are more informative than lumbar spine scans for monitoring your bone health trajectory. Consider establishing a baseline BMD measurement in your 40s if you have the AA genotype and additional risk factors (family history, low body weight, smoking, glucocorticoid use).

Interactions

Rs3801387 is in high linkage disequilibrium with other WNT16 variants including two missense SNPs (rs2707466 Thr>Ile and rs2908004 Gly>Arg) and rs7776725 in the adjacent FAM3C gene. These variants form haplotype blocks where the minor alleles generally cluster together and have a protective effect on BMD. When assessing bone health risk, consider that these variants act as a functional unit rather than independent factors.

WNT16 is part of the broader WNT signaling pathway, which includes other bone-related genes identified in GWAS such as LRP5, SOST, DKK1, and RANKL. However, WNT16's effect is uniquely cortical-specific, distinguishing it from pathway members that affect trabecular bone. This suggests that individuals with risk variants in both WNT16 and trabecular-affecting genes (like SOST) may face compounded fracture risk across multiple skeletal sites.

The interaction between rs3801387 genotype and vitamin D status deserves attention. A study in adolescents found multi-locus interactions between WNT16 rs3801387, vitamin D receptor (VDR), and vitamin D binding protein (VDBP) variants affecting serum vitamin D levels and bone quality ¹²¹² multi-locus interactions between WNT16 rs3801387, vitamin D receptor (VDR), and vitamin D binding protein (VDBP) variants affecting serum vitamin D levels and bone quality . While this finding needs replication, it suggests that individuals with the AA genotype may derive particular benefit from maintaining optimal vitamin D status, as the two systems appear to interact in regulating bone homeostasis.